These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Usefulness of the measurement of serum soluble IL-2 receptor alpha chain levels in clinical monitoring of non-Hodgkin lymphoma].
    Author: Setoyama Y, Imai J, Ishikawa T, Sakaida H, Takaori-Kondo A, Kawamata S, Uchiyama T.
    Journal: Rinsho Byori; 1994 Aug; 42(8):834-42. PubMed ID: 7933620.
    Abstract:
    We measured the serum concentrations of the soluble form of interleukin-2 receptor alpha chain (sIL-2R alpha) in 25 patients with non-Hodgkin lymphoma (NHL) and 1 patient with virus-associated hemophagocytic syndrome (VHAS) by an enzyme-linked immunosorbent assay (ELISA) using two anti-IL-2R alpha monoclonal antibodies which recognize different epitopes. The sIL-2R alpha levels were markedly higher (n = 12, range = 469.2-11020 U/ml, mean +/- SD = 6153.0 +/- 1687.2 U/ml) in the sera of patients with NHL than in healthy individuals (n = 46, range = 290.1-849.3 U/ml, mean +/- SD = 459.8 +/- 126.9 U/ml, p < 0.01). The serum sIL-2R alpha levels in the NHL patients were closely associated with the stage of disease. The mean value of the serum sIL-2R alpha in each stage of NHL was as follows: stage I (469.2 U/ml, n = 1), stage II (4879.0 U/ml, n = 3), stage III (7364.8 U/ml, n = 8), stage IV (13796.2 U/ml, n = 10). However, there was no clear correlation between the elevation of serum sIL-2R alpha level and the pathological (LSG) classification of NHL. The serum sIL-2R alpha levels serially measured during the clinical course of 2 NHL patients were closely associated with the severity and the progression of the disease. Thus, the measurement of serum sIL-2R alpha levels is very useful not only for the diagnosis but also to monitor the clinical course of NHL.
    [Abstract] [Full Text] [Related] [New Search]